Richard J. Nowak, MD, is director of the Myasthenia Gravis Clinic, director of Clinical & Translational Neuromuscular Research (CTNR), and associate professor of neurology at Yale School of Medicine.
Hosted on MSN
Emerging Myasthenia Gravis Treatments
The treatment pipeline for generalized myasthenia gravis (gMG) continues to be active, a consequence of the ongoing progress in knowledge that led to approval of six new drugs for the disease. In ...
Myasthenia gravis is a rare disease where the immune system attacks the communication between nerves and muscles, causing weakness. It often affects the muscles used for eye movement, facial ...
New York, March 10, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca’s ...
NEW HAVEN, Conn. (WTNH) — In today’s Health Headlines, June is Myasthenia Gravis Awareness Month. What is myasthenia gravis, how is it diagnosed, and what treatments are available? Dr. Kunal Desai, ...
The US Food and Drug Administration (FDA) has approved nipocalimab-aahu (Imaavy, Johnson & Johnson) for the treatment of generalized myasthenia gravis (gMG) in adults and adolescents 12 years of age ...
While Johnson & Johnson isn't the first to secure FDA approval for an FcRn-blocking antibody in myasthenia gravis, the New Jersey drugmaker is confident that a broad label will land its product an ...
New guidelines and advocacy enhance myasthenia gravis treatment access, promoting proactive management and improved insurance coverage for diverse patient populations. There are key systemic factors ...
A new study looked at mortality trends in the U.S. among more than 37,000 individuals with MG over a 23-year period. Age-adjusted mortality rates in MG increased significantly over the study period, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback